Of note, palbociclib, a selective CDK4/6 inhibitor (CDK4/6i), in combination with endocrine therapy, represents the first-line treatment for metastatic postmenopausal patients with estrogen receptor-positive and Her2 (Human epidermal growth factor receptor 2)-negative breast cancer [84]. This evidence concerns the gene ERBB2 and breast cancer.